MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524114 | Name: ABT-239

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ABT-239 is an H3-receptor inverse agonist developed by Abbott. It has stimulant and nootropic effects, and has been investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia. ABT-239 is more active at the human H3 receptor than comparable agents such as thioperamide, ciproxifan, and cipralisant.

Chemical Structure

ABT-239
ABT-239
CAS#460746-46-7

Theoretical Analysis

MedKoo Cat#: 524114

Name: ABT-239

CAS#: 460746-46-7

Chemical Formula: C22H22N2O

Exact Mass: 330.1732

Molecular Weight: 330.42

Elemental Analysis: C, 79.97; H, 6.71; N, 8.48; O, 4.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ABT-239; ABT 239; ABT239;
IUPAC/Chemical Name
4-(2-{2-[(2R)-2-Methylpyrrolidin-1-yl]ethyl}- benzofuran-5-yl)benzonitrile
InChi Key
KFHYZKCRXNRKRC-MRXNPFEDSA-N
InChi Code
InChI=1S/C22H22N2O/c1-16-3-2-11-24(16)12-10-21-14-20-13-19(8-9-22(20)25-21)18-6-4-17(15-23)5-7-18/h4-9,13-14,16H,2-3,10-12H2,1H3/t16-/m1/s1
SMILES Code
N#CC1=CC=C(C2=CC=C(OC(CCN3[C@H](C)CCC3)=C4)C4=C2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 330.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bhowmik M, Saini N, Vohora D. Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain Res. 2014 Sep 18;1581:129-40. doi: 10.1016/j.brainres.2014.06.012. Epub 2014 Jun 18. PubMed PMID: 24952295. 2: Kruk M, Miszkiel J, McCreary AC, Przegaliński E, Filip M, Biała G. Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice. Pharmacol Rep. 2012;64(6):1316-25. PubMed PMID: 23406742. 3: Munari L, Provensi G, Passani MB, Blandina P. Selective brain region activation by histamine H₃ receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression. Neuropharmacology. 2013 Jul;70:131-40. doi: 10.1016/j.neuropharm.2013.01.021. Epub 2013 Feb 1. PubMed PMID: 23380305. 4: Miszkiel J, Kruk M, McCreary AC, Przegaliński E, Biała G, Filip M. Effects of the histamine H3 receptor antagonist ABT-239 on acute and repeated nicotine locomotor responses in rats. Pharmacol Rep. 2011;63(6):1553-9. PubMed PMID: 22358104. 5: Varaschin RK, Akers KG, Rosenberg MJ, Hamilton DA, Savage DD. Effects of the cognition-enhancing agent ABT-239 on fetal ethanol-induced deficits in dentate gyrus synaptic plasticity. J Pharmacol Exp Ther. 2010 Jul;334(1):191-8. doi: 10.1124/jpet.109.165027. Epub 2010 Mar 22. PubMed PMID: 20308329; PubMed Central PMCID: PMC2912053. 6: Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther. 2005 Apr;313(1):165-75. Epub 2004 Dec 17. PubMed PMID: 15608078. 7: Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. Epub 2004 Dec 17. PubMed PMID: 15608077.